Jeon, Seong Ik Yang, Suah Shim, Man Kyu Kim, Kwangmeyung 2024-01-19T11:32:28Z 2024-01-19T11:32:28Z 2022-06-17 2022-08 1998-0124 https://pubs.kist.re.kr/handle/201004/114836 The cathepsin B-responsive prodrugs are promising strategies to reduce the serious adverse effects of anticancer drugs by improving the cancer selectivity that can be specifically activated by overexpressed cathepsin B in targeted cancer cells. However, clinical translation of such therapeutic approaches has been restricted by low antitumor efficacy that is mainly attributable to undesirable pharmacokinetic profiles and inefficient tumor-targeting of cathepsin B-responsive prodrugs, due to their small-molecule structure. In recent decades, many researchers have widely investigated the drug delivery system (DDS) to improve the in vivo pharmacokinetic profiles and tumor-targeting efficiency of cathepsin B-responsive prodrugs via the application of polymers, dendrimers, antibodies, lipids, and inorganic nanoparticles as drug carriers. In addition, the potential therapeutic efficacy of DDS for cathepsin B-responsive prodrugs is demonstrated in multiple studies and combinatorial treatment with typical therapeutic modalities can effectively overcome the challenges of tumor heterogeneity and multidrug resistance. In this review, recent advances and progress of new DDS for cathepsin B-responsive prodrugs are outlined, and their clinical trials are discussed. Besides, potential challenges and the outlooks for clinical translation of cathepsin B-responsive prodrugs are highlighted. English Tsinghua Univ Press Cathepsin B-responsive prodrugs for cancer-targeted therapy: Recent advances and progress for clinical translation Article 10.1007/s12274-022-4354-y 1 Nano Research, v.15, no.8, pp.7247 - 7266 Nano Research 15 8 7247 7266 N scie scopus 000807315400002 Chemistry, Physical Nanoscience & Nanotechnology Materials Science, Multidisciplinary Physics, Applied Chemistry Science & Technology - Other Topics Materials Science Physics Article ANTIBODY-DRUG CONJUGATE N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER-DOXORUBICIN IN-VITRO EVALUATION ALPHA TNF-ALPHA PHASE-I PACLITAXEL POLIGLUMEX MOLECULAR-WEIGHT PHOTODYNAMIC THERAPY COMBINATION THERAPY DELIVERY-SYSTEMS cathepsin B prodrug chemotherapy drug delivery system targeted cancer therapy